Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 2
1991 2
1994 1
1995 2
1996 1
2000 2
2001 1
2003 1
2004 1
2005 3
2006 3
2007 2
2008 1
2009 8
2010 5
2011 5
2012 3
2013 5
2014 9
2015 12
2016 26
2017 24
2018 27
2019 27
2020 32
2021 60
2022 48
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

282 results
Results by year
Filters applied: . Clear all
Page 1
'Long COVID' syndrome.
Taribagil P, Creer D, Tahir H. Taribagil P, et al. Among authors: tahir h. BMJ Case Rep. 2021 Apr 19;14(4):e241485. doi: 10.1136/bcr-2020-241485. BMJ Case Rep. 2021. PMID: 33875508 Free PMC article.
Current status of beta-thalassemia and its treatment strategies.
Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi SAR, Sadia, Irfan M, Khan MA. Ali S, et al. Among authors: tahir hm. Mol Genet Genomic Med. 2021 Dec;9(12):e1788. doi: 10.1002/mgg3.1788. Epub 2021 Nov 5. Mol Genet Genomic Med. 2021. PMID: 34738740 Free PMC article. Review.
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group. Mease PJ, et al. Among authors: tahir h. Ann Rheum Dis. 2020 Jan;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386. Epub 2019 Sep 28. Ann Rheum Dis. 2020. PMID: 31563894 Free PMC article. Clinical Trial.
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.
Mease PJ, Landewé R, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Readie A, Mpofu S, Delicha EM, Pricop L, van der Heijde D. Mease PJ, et al. Among authors: tahir h. RMD Open. 2021 Jul;7(2):e001600. doi: 10.1136/rmdopen-2021-001600. RMD Open. 2021. PMID: 34330846 Free PMC article. Clinical Trial.
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P. Smolen JS, et al. Among authors: tahir h. Ann Rheum Dis. 2020 Oct;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13. Ann Rheum Dis. 2020. PMID: 32660977 Free PMC article. Clinical Trial.
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.
van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L. van der Heijde D, et al. Among authors: tahir h. Rheumatology (Oxford). 2020 Jun 1;59(6):1325-1334. doi: 10.1093/rheumatology/kez420. Rheumatology (Oxford). 2020. PMID: 31586420 Free PMC article. Clinical Trial.
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study.
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S; FUTURE 1 study group. Mease PJ, et al. Among authors: tahir h. ACR Open Rheumatol. 2020 Jan;2(1):18-25. doi: 10.1002/acr2.11097. Epub 2019 Nov 14. ACR Open Rheumatol. 2020. PMID: 31943974 Free PMC article.
Emerging COVID-19 vaccines: A rheumatology perspective.
Byravan S, Fardanesh A, Tahir H, Moorthy A. Byravan S, et al. Among authors: tahir h. Int J Rheum Dis. 2021 Feb;24(2):144-146. doi: 10.1111/1756-185X.14048. Int J Rheum Dis. 2021. PMID: 33523564 Free PMC article. No abstract available.
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K. Mease P, et al. Among authors: tahir h. Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: 10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17. Ann Rheum Dis. 2018. PMID: 29550766 Free PMC article. Clinical Trial.
282 results